| ²é¿´: 762 | »Ø¸´: 1 | ||||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||||
rhett82½ð³æ (СÓÐÃûÆø)
ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ ...
|
[½»Á÷]
GMP´Ê»ãÒ»
|
|||
|
¸üÒÂÊÒ Changing Room Ò»¸ü First Changing Room ÊÖÏûÊÒ Hands Disinfection Room ÆøÕ¢ÊÒ Airlock Room ½à¾ßÊÒ Cleaning Tools Room ÇåÏ´ÊÒ Cleaning Room Ä£¾ßÊÒ Dies Room ÄÚ°ü×°ÊÒ Immediate Package Room °²È«ÃÅ Emergency Door Íâ°üÇåÊÒ Outer Package Removing Room ´æÁϼä Storage Room of Raw Materials ·ÛËéÊÒ Pulverizing Room ±¸ÁÏÊÒ Materials Preparing Room Ó²½ºÊÒ Hard Capsules Filling Room Èí½ºÊÒ Soft Capsules Room ÖÆÁ£¸ÉÔïÊÒ Granulating and Drying Room ×Ü»ì¼ä Blending Room ÖмäÕ¾ Intermediate Station ѹƬÊÒ Tablets Room Compression Room °üÒÂÊÒ Coating Room Å佬¼ä Coating Mixture Preparing Room ÂÁËܰü×°¼ä Packing Room ´«µÝ´° Transferring Window Íâ°ü×°ÊÒ Outer Packing Room ÕôÁóË®ÊÒ Water Purifying Room ÖʼìÊÒ Quality Control Room ŨÅäÊÒ Concentrated Solution Room Ï¡ÅäÊÒ Diluted Solution Room BATCH PRODUCTION£ºÅúÁ¿Éú²ú£»·ÖÅúÉú²ú BATCH PRODUCTION RECORDS£ºÉú²úÅúºÅ¼Ç¼ POST-OR PRE- MARKET SURVEILLANCE£ºÏúÊÛǰ»òÏúÊÛºó¼à¶½ INFORMED CONSENT£ºÖªÇéͬÒ⣨»¼Õß¶ÔÖÎÁÆ»òÊÜÊÔÕß¶ÔÒ½ÁÆÊÔÑéÁ˽âºó±íʾͬÒâ½ÓÊÜÖÎ ÁÆ»òÊÔÑ飩 PRESCRIPTION DRUG£º´¦·½Ò© OTC DRUG£¨OVER¡ªTHE¡ªCOUNTER DRUG£©£º·Ç´¦·½Ò© U£®S£®PUBLIC HEALTH SERVICE£ºÃÀ¹úÎÀÉú¸£Àû²¿ Ò©Æ·ÖÆ±¸ preparation of drug products Õë¶Ô pertain to ÈËÓÃÉúÎïÖÆÆ· biological products for human use ²¹³ä supplement ´úÌæÌõÀý supersede the requlation ÌáÒéÃâ³ý proposed exemption Ò»°ãÏúÊÛºÍÏû·Ñ ordinarily marketed and consumed ÃÀµÂ£¬Óŵ㣬ЧÁ¦ virtue Áª°î×¢²á±í FR/federal register ÈËÓÃÎïÆ· human foods ÓÃÓÚ¼ø±ð£¬²â¶¨ shall be applied in determining Éú²ú£¬¼Ó¹¤£¬°ü×°£¬Öü´æ manufacture,process,pack,hold, Ö°ÔðºÍȨÁ¦ responsibility and authority Åú×¼ºÍ¾ÜÊÕ approve or reject/withhold ¸´²éÉú²ú¼Ç¼ review production records ¶ÔqcÀ´Ëµ¿ÉÒÔ»ñµÃµÄ shall be available to QC Êʵ±µÄ adequate Ч¼ÛºÍº¬Á¿ strength Ìṩ֤Ã÷Îļþ shall be documented ·ûºÏ conform to ÖÆ¶©ÍêÉÆ sound ÿװ»õÁ¿ each shipment ±äÖ浀 is subject to deterioration accommodation (³µ£¬´¬£¬·É»úµÈµÄ)Ô¤¶¨ÆÌλ ÅúºÅ batch Óк¦Î¢ÉúÎï objectionable microorganism ÁªºÏÅúºÅ the number of units ׼ȷÐÔ£¬ÁéÃôÐÔ£¬ÌØÒìÐÔ£¬Öظ´ÐÔ accuracy, sensitivity, specificity, and reproducibility ÌØÕ÷£¬ÊôÐÔ attribute ÅäÎé reconstitution Éè¼Æ project Ë³ÊÆÖÎÁÆÒ©Æ· homeopathic drug products ¿ÉÅäÎéÐÔ compatibility ±êÃ÷ purporting to Ó¦³ÉÎIJ¢×ñÑ shall be in writing and shall be followed. ¿É¼ì³öˮƽ detectable levels ͨ¹ý²Î¿¼ÎÄÏ×¾ßÌ廯 incorporated by reference ¸±×÷Óà adeverse/side effect ÀàÐÍ type »ì·Å mixups Ç©ÊÕ receipt ´¦Àí disposition ÕýѹϹýÂË be filtered under positive pressure ²ãÁ÷»ò·Ç²ãÁ÷ laminar or nonlaminar; ÎÞ¾ú»·¾³ aseptic conditions ÕÕÃ÷ lighting ͨ·ç¡¢¿ÕÆø¹ýÂË¡¢¿ÕÆø¼ÓÈÈÓëÀäÈ´ Ventilation, air filtration, air heating and cooling. ¿ÕÆøÊäËÍϵͳ Air-handling systems ¸½½ü½¨ÖþÎï immediate premises רÓÃë½í single-service towels ½øÁÏ Charge-in ±êʾÁ¿»ò¹æ¶¨Á¿ labeled or established amount ʵ¼Ê²úÁ¿ Actual yields ÀíÂÛ²úÁ¿ theoretical yields Éú²úÖÜÆÚ the production of a batch of a drug product Ò©Æ·µÄÒ»ÖÂÐÔºÍÍêÕûÐÔ uniformity and integrity of drug products ±À½âʱ¼ä Disintegration time ÈÜÒºµÄ³ÎÃ÷¶È¡¢ÈܽâÍêÈ«ÐÔ¼°pHÖµ Clarity, completeness, or pH of solutions Îȶ¨ÐÔÆÀ¹À variability estimates װж handling NIH£¨NATIONAL INSTITUTE OF HEALTH£©£º£¨ÃÀ¹ú£©È«¹úÎÀÉúÑо¿Ëù CLINICAL TRIAL£ºÁÙ´²ÊÔÑé ANIMAL TRIAL£º¶¯ÎïÊÔÑé ACCELERATED APPROVAL£º¼ÓËÙÅú×¼ FDA£¨FOOD AND DRUG ADMINISTRATION£©£º£¨ÃÀ¹ú£©Ê³Æ·Ò©Æ·¹ÜÀí¾Ö IND£¨INVESTIGATIONAL NEW DRUG£©£ºÁÙ´²Ñо¿ÉêÇ루ָÉ걨½×¶Î£¬Ïà¶Ô ÓÚNDA¶øÑÔ£©£»Ñо¿ÖеÄÐÂÒ©£¨Ö¸ÐÂÒ©¿ª·¢½×¶Î£¬Ïà¶ÔÓÚÐÂÒ©¶øÑÔ£¬¼´ÁÙ´²Ç°Ñо¿½áÊø£© NDA£¨NEW DRUG APPLICATION£©£ºÐÂÒ©ÉêÇë ANDA£¨ABBREVIATED NEW DRUG APPLICATION£©£º¼ò»¯ÐÂÒ©ÉêÇë EPËߣ¨EXPORT APPLICATION £©£º³ö¿ÚÒ©ÉêÇ루ÉêÇë³ö¿Ú²»±»Åú×¼ÔÚÃÀ¹ú ÏúÊÛµÄÒ©Æ·£© TREATMENT IND£ºÑо¿ÖеÄÐÂÒ©ÓÃÓÚÖÎÁÆ ABBREVIATED£¨NEW£©DRUG£º¼ò»¯ÉêÇëµÄÐÂÒ© DMF£¨DRUG MASTER FILE£©£ºÒ©ÎïÖ÷Îļþ£¨³ÖÓÐÕßΪ½÷É÷Æð¼û¶ø×¼±¸µÄ±£ ÃÜ×ÊÁÏ£¬¿ÉÒÔ°üÀ¨Ò»¸ö»ò¶à¸öÈËÓÃÒ©ÎïÔÚÖÆ±¸¡¢¼Ó¹¤¡¢ °ü×°ºÍÖü´æ¹ý³ÌÖÐËù¼°µÄÉ豸¡¢Éú²ú¹ý³Ì»òÎïÆ·¡£Ö»ÓÐÔÚDMF³ÖÓÐÕß»òÊÚȨ´ú±íÒÔÊÚȨÊéµÄÐÎʽÊÚȨ¸øFDA£¬FDAÔÚÉó²éIND¡¢NDA¡¢ANDAʱ²ÅÄܲο¼ÆäÄÚÈÝ£© HOLDER£ºDMF³ÖÓÐÕß CFR£¨CODE OF FEDERAL REGULATION£©£º£¨ÃÀ¹ú£©Áª°î·¨¹æ PANEL£º×¨¼ÒС×é BATCH PRODUCTION£ºÅúÁ¿Éú²ú£»·ÖÅúÉú²ú BATCH PRODUCTION RECORDS£ºÉú²úÅúºÅ¼Ç¼ POST-OR PRE- MARKET SURVEILLANCE£ºÏúÊÛǰ»òÏúÊÛºó¼à¶½ INFORMED CONSENT £ºÖªÇéͬÒ⣨»¼Õß¶ÔÖÎÁÆ»òÊÜÊÔÕß¶ÔÒ½ÁÆÊÔÑéÁ˽âºó±íʾͬÒâ½ÓÊÜÖÎÁÆ»òÊÔÑ飩 PRESCRIPTION DRUG£º´¦·½Ò© OTC DRUG£¨OVER¡ªTHE¡ªCOUNTER DRUG£©£º·Ç´¦·½Ò© U£®S£®PUBLIC HEALTH SERVICE£ºÃÀ¹úÎÀÉú¸£Àû²¿ NIH£¨NATIONAL INSTITUTE OF HEALTH£©£º£¨ÃÀ¹ú£©È«¹úÎÀÉúÑо¿Ëù CLINICAL TRIAL£ºÁÙ´²ÊÔÑé ANIMAL TRIAL£º¶¯ÎïÊÔÑé ACCELERATED APPROVAL£º¼ÓËÙÅú×¼ Acceptance Criteria ¨C ½ÓÊÕ±ê×¼ ½ÓÊÕ²âÊÔ½á¹ûµÄÊý×ÖÏÞ¶È¡¢·¶Î§»òÆäËüºÏÊʵÄÁ¿¶È±ê×¼¡£ Active Pharmaceutical Ingredient (API)(or Drug Substance) ¨C »îÐÔÒ©ÓÃ³É·Ö (ÔÁÏÒ©) Ö¼ÔÚÓÃÓÚÒ©Æ·ÖÆÔìÖеÄÈκÎÒ»ÖÖÎïÖÊ»òÎïÖʵĻìºÏÎ¶øÇÒÔÚÓÃÓÚÖÆÒ©Ê±£¬³ÉΪҩƷµÄÒ»ÖÖ»îÐԳɷ֡£´ËÖÖÎïÖÊÔÚ¼²²¡µÄÕï¶Ï£¬ÖÎÁÆ£¬Ö¢×´»º½â£¬´¦Àí»ò¼²²¡µÄÔ¤·ÀÖÐÓÐÒ©Àí»îÐÔ»òÆäËüÖ±½Ó×÷Ó㬻òÕßÄÜÓ°Ïì»úÌåµÄ¹¦Äܺͽṹ¡£ API Starting Material ¨C ÔÁÏÒ©µÄÆðʼÎïÁÏ ÓÃÔÚÔÁÏÒ©Éú²úÖеģ¬ÒÔÖ÷Òª½á¹¹µ¥Ôª±»²¢Èë¸ÃÔÁÏÒ©µÄÔÁÏ¡¢ÖмäÌå»òÔÁÏÒ©¡£ÔÁÏÒ© µÄÆðʼÎïÁÏ¿ÉÄÜÊÇÔÚÊг¡ÉÏÓÐÊÛ£¬Äܹ»¸ù¾ÝºÏͬ»òÉÌÒµÐÒé´ÓÒ»¸ö»ò¶à¸ö¹©Ó¦ÉÌ´¦¹ºµÃ£¬»òÕß×Ô¼ºÉú²ú¡£ÔÁÏÒ©µÄÆðʼÎïÁÏͨ³£ÓÐÌØ¶¨µÄ»¯Ñ§ÌØÐԺͽṹ¡£ Batch (or Lot) ¨C Åú ÓÉÒ»¸ö»òһϵÁй¤ÒÕ¹ý³ÌÉú²úµÄÒ»¶¨ÊýÁ¿µÄÎïÁÏ£¬Òò´ËÔڹ涨µÄÏÞ¶ÈÄÚÊǾùÒ»µÄ¡£ÔÚÁ¬ÐøÉú²úÖУ¬Ò»Åú¿ÉÄܶÔÓ¦ÓÚÓëÉú²úµÄÄ³Ò»ÌØ¶¨²¿·Ö¡£ÆäÅúÁ¿¿É¹æ¶¨ÎªÒ»¸ö¹Ì¶¨ÊýÁ¿£¬»òÔڹ̶¨Ê±¼ä¼ä¸ôÄÚÉú²úµÄÊýÁ¿¡£ Batch Number (or Lot Number) ¨C ÅúºÅ ÓÃÓÚ±êʶһÅúµÄÒ»¸öÊý×Ö¡¢×ÖĸºÍ/»ò·ûºÅµÄΨһ×éºÏ£¬´ÓÖпÉÈ·¶¨Éú²úºÍÏúÊÛµÄÀúÊ·¡£ Bioburden ¨C ÉúÎï¸ºÔØ ¿ÉÄÜ´æÔÚÓÚÔÁÏ¡¢ÔÁÏÒ©µÄÆðʼÎïÁÏ¡¢ÖмäÌå»òÔÁÏÒ©ÖеÄ΢ÉúÎïµÄˮƽºÍÖÖÀà(ÀýÈ磬Ö²¡µÄ»ò²»Ö²¡µÄ)¡£ÉúÎï¸ºÔØ²»Ó¦µ±µ±×÷ÎÛȾ£¬³ý·Çº¬Á¿³¬±ê£¬»òÕß²âµÃÖ²¡ÉúÎï¡£ Calibration ¨C УÑé Ö¤Ã÷ij¸öÒÇÆ÷»ò×°ÖÃÔÚÒ»Êʵ±µÄÁ¿³Ì·¶Î§ÄÚËù²âµÃµÄ½á¹ûÓëÒ»²ÎÕÕÎ»ò¿É×·Ëݵıê×¼Ïà±ÈÔڹ涨ÏÞ¶ÈÄÚ¡£ Computer System ¨C ¼ÆËã»úϵͳ Éè¼Æ°²×°ÓÃÓÚÖ´ÐÐijһÏî»òÒ»×鹦ÄܵÄÒ»×éÓ²¼þÔª¼þºÍ¹ØÁªµÄÈí¼þ¡£ Computerized System ¨C ¼ÆËã»ú»¯ÏµÍ³ Óë¼ÆËã»úϵͳÕûºÏµÄÒ»¸ö¹¤ÒÕ»ò²Ù×÷¡£ Contamination ¨C ÎÛȾ ÔÚÉú²ú¡¢È¡Ñù¡¢°ü×°»òÖØÐ°ü×°¡¢Öü´æ»òÔËÊä¹ý³ÌÖУ¬¾ß»¯Ñ§»ò΢ÉúÎïÐÔÖʵÄÔÓÖÊ»òÍâÀ´ÎïÖʽøÈë»òմȾÔÁÏ¡¢ÖмäÌå»òÔÁÏÒ©¡£ Contract Manufacturer ¨C ÐÒéÖÆÔìÉÌ ´ú±íÔÖÆÔìÉ̽øÐв¿·ÖÖÆÔìµÄÖÆÔìÉÌ¡£ Critical ¨C ¾ö¶¨Ð﵀ ÓÃÀ´ÃèÊöΪÁËÈ·±£ÔÁÏÒ©·ûºÏ¹æ¸ñ±ê×¼£¬±ØÐë¿ØÖÆÔÚÔ¤¶¨·¶Î§ÄڵŤÒÕ²½Öè¡¢¹¤ÒÕÌõ¼þ¡¢²âÊÔÒªÇó»òÆäËüÓйزÎÊý»òÏîÄ¿¡£ Cross-Contamination ¨C ½»²æÎÛȾ Ò»ÖÖÎïÁÏ»ò²úÆ·¶ÔÁíÒ»ÖÖÎïÁÏ»ò²úÆ·µÄÎÛȾ¡£ Deviation ¨C Æ«²î ¶ÔÅú×¼µÄÖ¸Áî»ò¹æ¶¨µÄ±ê×¼µÄÆ«Àë¡£ Drug (Medicinal) Product ¨C Ò©Æ· ¾×îºó°ü×°×¼±¸ÏúÊÛµÄÖÆ¼Á(²Î¼ûQ1A)¡£ Drug Substance ¨C Ò©Îï ¼ûÔÁÏÒ© Expiry Date (or Expiration Date) ¨C ÓÐЧÆÚ ÔÁÏÒ©ÈÝÆ÷/±êÇ©ÉÏ×¢Ã÷µÄÈÕÆÚ£¬Ôڴ˹涨ʱ¼äÄÚ£¬¸ÃÔÁÏÒ©Ôڹ涨Ìõ¼þÏÂÖü´æÊ±£¬ÈÔ·ûºÏ¹æ¸ñ±ê×¼£¬³¬¹ýÕâÒ»ÆÚÏÞÔò²»Ó¦µ±Ê¹ÓᣠImpurity ¨C ÔÓÖÊ ´æÔÚÓÚÖмäÌå»òÔÁÏÒ©ÖУ¬Èκβ»Ï£ÍûµÃµ½µÄ³É·Ö¡£ Impurity Profile ¨C ÔÓÖʸſö ¶Ô´æÔÚÓÚÒ»ÖÖÔÁÏÒ©ÖеÄÒÑÖªºÍδ֪ÔÓÖʵÄÃèÊö¡£ In-Process Control (or Process Control) ¨C ÖÐ¼ä¿ØÖÆ Éú²ú¹ý³ÌÖÐΪ¼à²â£¬ÔÚ±ØÒªÊ±µ÷½Ú¹¤ÒÕºÍ/»ò±£Ö¤ÖмäÌå»òÔÁÏÒ©·ûºÏÆä¹æ¸ñ¶ø½øÐеļì²é¡£ Intermediate ¨C ÖмäÌå ÔÁÏÒ©¹¤ÒÕ²½ÖèÖвúÉúµÄ¡¢±ØÐë¾¹ý½øÒ»²½·Ö×ӱ仯»ò¾«ÖƲÅÄܳÉΪÔÁÏÒ©µÄÒ»ÖÖÎïÁÏ¡£ÖмäÌå¿ÉÒÔ·ÖÀë»ò²»·ÖÀë¡£(×¢£º±¾Ö¸ÄÏֻɿ¼°¸Ã¹«Ë¾¶¨ÒåΪÔÁÏÒ©Éú²úÆðʼµãÒÔºóÉú²úµÄÖмäÌå¡£) Lot ¨C Åú ¼ûÅú(Batch)¡£ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ºÏ³É¹¤ÒÕ |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ9È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ10È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

kianna
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 18.2
- Ìû×Ó: 46
- ÔÚÏß: 2.7Сʱ
- ³æºÅ: 150246
- ×¢²á: 2005-12-29
- ÐÔ±ð: MM
- רҵ: ҩѧ
2Â¥2007-04-02 15:40:37













»Ø¸´´ËÂ¥
